Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Stock Information for Genenta Science S.p.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Genenta Science S.p.A.

Genenta to Present at Upcoming Scientific and Investor Conferences
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
The European Commission Grants Orphan Drug Designation to Temferon(TM) for Treatment of Glioma
Genenta to Provide Update on Lead Product Temferon(TM)
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.